This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Why Have A Benchmark explains the rationale for benchmarks in monitoring performance, setting goals, and communicating results clearly.
25,850 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
You don’t need a wall street star to beat the market. A thoughtfully chosen low-cost that could outperform fund manag...
Q1 2026 earnings transcripts reveal more than quarterly numbers. Explore how guidance, margin trends, and management ...
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Modine Manufacturing sits at a compelling crossroads as data centers expand. This primer outlines why investors may w...
A fresh cash-raising move and a strategic acquisition shook investors in Intuitive Machines. This article breaks down...
When the market wakes up to a notable move in Smucker shares, it often signals more than a one-off beat. This article...
A growing family and a high-profile destination wedding are on the horizon for billionaire John Paulson and his fianc...
SpaceX grabs headlines, yet smart investors look for real performance. Meet two growth stocks I prefer over the hype:...
When a scam moves from phone calls to an in-person cash exchange, investigators may stage a sting. This article explo...
Investors rushed to understand why intuitive surgical stock dropped this week. This article dissects the catalysts, g...
ValueAct Holdings’ move to reduce its stake in Insight Enterprises signals a shifting landscape for enterprise IT spe...